Severe Lung Disease in Childhood
Long Term Outcome of Severe Lung Disease in Childhood
Only little information exists about the long term consequences of having severe lung disease in childhood. The patient population is heterogenous and the prognostic markers are few.
This observational study will investigate which parameters that can be used to predict the outcome of having severe lung disease in childhood.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
All patients aged 0-18 years at the HCA Childrens Hospital with a severe lung disease will prospectively be registered in a database.
At a yearly follow up, data from the patient record will be registered. Informed consent from the patients and/or their parents will be obtained. Registered data will include height, weight, results of lung function tests and imaging diagnostics.
The study will provide knowledge of the prognosis of different lung diseases and how to monitor lung function in children.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Josefine Gradman, PhD
- Phone Number: 0045 29241375
- Email: josefine.gradman@rsyd.dk
Study Locations
-
-
-
Odense, Denmark, 5000
- Recruiting
- Hans Christian Andersen Children's Hospital
-
Contact:
- Josefine Gradman, PhD
- Phone Number: 0045 29241375
- Email: josefine.gradman@rsyd.dk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria: severe lung disease -
Exclusion Criteria: no informed consent
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FEV1
Time Frame: 18 years
|
liter
|
18 years
|
|
FVC
Time Frame: 18 years
|
liter
|
18 years
|
|
Lung Clearance Index (LCI)
Time Frame: 18 years
|
number
|
18 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
height
Time Frame: 18 years
|
meters
|
18 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Josefine Gradman, PhD, Odense University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HCA-Lung
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.